Analyst Emily Bodnar from H.C. Wainwright reiterated a Buy rating on Arcus Biosciences and increased the price target to $32.00 from $28.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Emily Bodnar has given her Buy rating due to a combination of factors that highlight Arcus Biosciences’ strategic focus and financial positioning. The company has decided to discontinue certain trials in gastrointestinal cancer, which, although not surprising, allows Arcus to streamline its resources towards more promising areas. This strategic shift is expected to extend the company’s cash runway into 2028, providing a solid financial foundation for future developments.
Arcus is concentrating its efforts on casdatifan (cas) development in metastatic clear cell renal cell carcinoma (ccRCC) and its emerging inflammation and autoimmune (I&I) portfolio. The ongoing trials and potential expansions in these areas, particularly with the promising safety and efficacy profile of casdatifan, are seen as key value drivers. Furthermore, the company’s early-stage immunology pipeline, including the MRGPRX2 inhibitor, is poised to enter clinical trials, potentially opening new therapeutic avenues. These strategic initiatives underscore Arcus’ potential for growth and innovation, supporting the Buy rating.
Bodnar covers the Healthcare sector, focusing on stocks such as Olema Pharmaceuticals, AnaptysBio, and Arcus Biosciences. According to TipRanks, Bodnar has an average return of 15.6% and a 37.22% success rate on recommended stocks.
In another report released today, Wells Fargo also assigned a Buy rating to the stock with a $30.00 price target.